Climb Bio (CLYM) grants 300,000 stock options to Chief Business Officer

Rhea-AI Filing Summary

Climb Bio, Inc. (CLYM) reported a stock option grant to Chief Business Officer Megan Wilson Perrin on a Form 4. On January 6, 2026, she received a stock option to buy 300,000 shares of common stock at an exercise price of $3.81 per share, expiring on January 5, 2036.

According to the vesting terms, 25% of the option shares vest on the first anniversary of the grant date, with the remaining shares vesting in 36 equal monthly installments through January 6, 2030, conditioned on her continued service with the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wilson Perrin Megan

(Last) (First) (Middle)

C/O CLIMB BIO, INC.

20 WILLIAM STREET, SUITE 145

(Street)

WELLESLEY HILLS MA 02481

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Climb Bio, Inc. [ CLYM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.81	01/06/2026		A		300,000		(1)	01/05/2036	Common Stock	300,000	$0.00	300,000	D

Explanation of Responses:

1. This option was granted on January 6, 2026 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 6, 2030, subject to the Reporting Person's continued service.

	/s/ Chandra Adams, as Attorney-in-Fact	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Climb Bio (CLYM) report on this Form 4?

The Form 4 reports that Megan Wilson Perrin, Chief Business Officer of Climb Bio, Inc., received a stock option grant for 300,000 shares of common stock.

What are the key terms of Megan Wilson Perrin’s stock option from Climb Bio (CLYM)?

The option allows her to buy 300,000 shares of Climb Bio common stock at an exercise price of $3.81 per share, with an expiration date of January 5, 2036.

How do the Climb Bio (CLYM) stock options granted to the CBO vest?

The option vests as follows: 25% of the shares vest on the first anniversary of the January 6, 2026 grant date, and the remaining shares vest in 36 equal monthly installments through January 6, 2030, subject to continued service.

How many derivative securities does the reporting person hold after this Climb Bio (CLYM) transaction?

After the reported transaction, 300,000 stock options are shown as beneficially owned by the reporting person.

Is the reported Climb Bio (CLYM) stock option held directly or indirectly?

The Form 4 shows the 300,000 stock options as held with direct (D) ownership by the reporting person.

What role does the reporting person hold at Climb Bio (CLYM)?

The reporting person, Megan Wilson Perrin, is identified as an officer of Climb Bio, serving as its Chief Business Officer.